The oxylipin analogue CS585 prevents platelet activation and thrombosis through activation of the prostacyclin receptor

Cardiovascular disease remains the primary cause of morbidity and mortality globally. Platelet activation is critical for maintaining hemostasis and preventing leakage of blood cells from the vessel. There has been a paucity in the development of new drugs to target platelet reactivity. Recently, the oxylipin 12-HETrE, produced in the platelet, was shown to limit platelet reactivity through activation of the prostacyclin receptor. Here, we demonstrate the synthesis of a novel analogue …